Active Ingredient History
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Chordoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophagogastric Junction (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Immune Checkpoint Inhibitors (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Melanoma (Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Sarcoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue